Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition high risk for severe COVID-19. MEDLINE, Embase, Cochrane databases were searched relevant articles from January 1, 2019 to February 9, 2024. Studies reporting data two doses vaccination adults conditions developing COVID-19 according US Centers Disease Control Prevention included. Outcomes interest SARS-CoV-2 infection (overall, symptomatic, severe), hospitalization due COVID-19, death Risk ratios (RRs) calculated random effects models. Subgroup analyses by specific conditions, number vaccinations, age, variant conducted. Heterogeneity between studies was estimated chi-square testing. The certainty evidence assessed using Grading Recommendations, Assessments, Development, Evaluations framework. Sixty-five observational capturing original/ancestral-containing primary series Omicron-containing bivalent original-BA4-5 vaccinations included meta-analysis. associated significantly lower (RR, 0.85 [95% CI, 0.79–0.92]; I2 = 92.5%), symptomatic 0.75 0.65–0.86]; 62.3%), 0.83 0.78–0.89]; 38.0%), 0.88 0.82–0.94]; 38.7%), 0.84 0.76–0.93]; 1.3%) than BNT162b2. Findings generally consistent across subgroups. Evidence low or very because sufficiently powered randomized controlled trials are impractical this heterogeneous population. Meta-analysis 65 showed that a COVID-19-related

Language: Английский

Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults With Underlying Medical Conditions: A Systematic Literature Review and Pairwise Meta-Analysis Using GRADE

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 14, 2024

ABSTRACT Introduction This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b in patients with at least one underlying medical condition high risk for severe COVID-19. Methods MEDLINE, Embase, Cochrane databases were searched relevant articles from January 1, 2019 to February 9, 2024. Studies reporting data two doses BNT162b2 vaccination adults conditions developing COVID-19 according US Centers Disease Control Prevention included. Outcomes interest SARS-CoV-2 infection (overall, symptomatic, severe), hospitalization due COVID-19, death Risk ratios (RRs) calculated random effects models. Subgroup analyses by specific conditions, number vaccinations, age, variant conducted. Heterogeneity between studies was estimated chi-square testing. The certainty evidence assessed using Grading Recommendations, Assessments, Development, Evaluations framework. Results Sixty-five observational capturing original/ancestral-containing primary series Omicron-containing bivalent original-BA4-5 vaccinations included meta-analysis. associated significantly lower (RR, 0.85 [95% CI, 0.79–0.92]; I 2 =92.5%), symptomatic 0.75 0.65–0.86]; =62.3%), 0.83 0.78–0.89]; =38.0%), 0.88 0.82–0.94]; =38.7%), 0.84 0.76–0.93]; =1.3%) than BNT162b2. Findings generally consistent across subgroups. Evidence low or very because sufficiently powered randomized controlled trials are impractical this heterogeneous population. Conclusion Meta-analysis 65 showed that a COVID-19-related

Language: Английский